Fishman Jay A Ltd. MI Reduces Stock Position in HCA Healthcare Inc (NYSE:HCA)

Fishman Jay A Ltd. MI trimmed its holdings in HCA Healthcare Inc (NYSE:HCA) by 3.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,375 shares of the company’s stock after selling 75 shares during the period. Fishman Jay A Ltd. MI’s holdings in HCA Healthcare were worth $286,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Westside Investment Management Inc. acquired a new position in HCA Healthcare during the second quarter worth $34,000. Doyle Wealth Management acquired a new stake in shares of HCA Healthcare in the second quarter valued at $34,000. North Star Investment Management Corp. acquired a new stake in shares of HCA Healthcare in the third quarter valued at $42,000. Coastal Investment Advisors Inc. acquired a new stake in shares of HCA Healthcare in the third quarter valued at $42,000. Finally, NEXT Financial Group Inc acquired a new stake in shares of HCA Healthcare in the second quarter valued at $43,000. Institutional investors own 70.19% of the company’s stock.

HCA Healthcare stock traded up $0.63 during midday trading on Friday, reaching $136.84. The company’s stock had a trading volume of 862,637 shares, compared to its average volume of 1,658,266. HCA Healthcare Inc has a fifty-two week low of $110.31 and a fifty-two week high of $147.42. The company has a market cap of $45.57 billion, a P/E ratio of 14.01, a P/E/G ratio of 1.14 and a beta of 0.90. The business has a 50-day simple moving average of $124.24 and a 200-day simple moving average of $127.34.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.23 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.10. The company had revenue of $12.69 billion for the quarter, compared to analysts’ expectations of $12.48 billion. HCA Healthcare had a negative return on equity of 173.49% and a net margin of 6.98%. HCA Healthcare’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the firm earned $2.16 earnings per share. As a group, equities research analysts forecast that HCA Healthcare Inc will post 10.52 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Shareholders of record on Monday, December 2nd will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Friday, November 29th. HCA Healthcare’s payout ratio is 16.38%.

In related news, insider A Bruce Moore, Jr. sold 14,450 shares of the firm’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $135.08, for a total transaction of $1,951,906.00. Following the transaction, the insider now owns 239,035 shares of the company’s stock, valued at $32,288,847.80. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jon M. Foster sold 19,477 shares of the firm’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $132.35, for a total value of $2,577,780.95. Following the transaction, the insider now directly owns 10,015 shares in the company, valued at approximately $1,325,485.25. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,553 shares of company stock worth $5,282,165. Corporate insiders own 2.70% of the company’s stock.

Several analysts have recently issued reports on the company. Mizuho set a $153.00 price objective on HCA Healthcare and gave the company a “buy” rating in a research note on Wednesday, July 31st. Stephens set a $150.00 price objective on HCA Healthcare and gave the company a “buy” rating in a research note on Wednesday, August 7th. Bank of America upgraded HCA Healthcare from an “underperform” rating to a “neutral” rating and increased their price objective for the company from $130.00 to $137.00 in a research note on Friday, September 6th. Robert W. Baird increased their price objective on HCA Healthcare from $155.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, UBS Group increased their price objective on HCA Healthcare from $165.00 to $168.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $155.07.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Further Reading: How much can an individual set aside as a catch-up contribution?

Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare Inc (NYSE:HCA).

Institutional Ownership by Quarter for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.